The Safety & Efficacy of Etanercept in Psoriasis Patients Who Have Not Responded to Adalimumab
Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
To describe the response of etanercept after adalimumab has failed to produce a satisfactory
response in moderate to severe plaque psoriasis. A total of 10 patients with moderate to
severe psoriasis who are currently using adalimumab for at least 12 weeks but have a PGA of
mild or worse will be transitioned to etanercept 50 mg twice weekly (BIW) for 12 wks followed
by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.